R M Stone
Affiliation: Massachusetts General Hospital
- Treatment options for myelodysplastic syndromesRichard Stone
Adult Leukemia Program, Dana Farber Cancer Institute, Boston, MA 02115, USA
Cancer Control 11:7-10. 2004
- Highlights in acute myeloid leukemia from the 2012 meeting of the American Society of HematologyRichard M Stone
Dana Farber Cancer Institute, Harvard Medical School, 450 Brookline Avenue, M1b 17, Boston, MA 02215, USA
Expert Rev Hematol 6:127-9. 2013..This year's meeting was held in Atlanta, GA, USA. Presentations included a wide variety of topics in benign and malignant hematology...
- Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemiaR M Stone
Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA
Leukemia 26:2061-8. 2012..A phase III prospective trial is ongoing (CALGB 10603, NCT00651261)...
- Is it time to revisit standard post-remission therapy?Richard M Stone
Harvard Medical School, Boston, MA, USA
Best Pract Res Clin Haematol 25:437-41. 2012..Future approaches, badly needed in older AML patients, may include the addition of new agents to currently used therapies or maintenance with DNA methyltransferase inhibitors...
- Novel therapeutic agents in acute myeloid leukemiaRichard M Stone
Harvard Medical School and Leukemia Program, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
Exp Hematol 35:163-6. 2007....
- A phase II study of continuous infusion homoharringtonine and cytarabine in newly diagnosed patients with chronic myeloid leukemia: CALGB study 19804Richard M Stone
Dana Farber Cancer Institute, Room M1B 17, 44 Binney St, Boston, MA, 02115, USA
Cancer Chemother Pharmacol 63:859-64. 2009..Both homoharringtonine (HHT), an alkaloid derivative from the Chinese yew tree that inhibits protein synthesis, and low-dose cytarabine have independent activity in CML and have been used in combination after failure of interferon therapy...
- Low dose interleukin-2 following intensification therapy with high dose cytarabine for acute myelogenous leukemia in first complete remissionRichard M Stone
Department of Medical Oncology, Division of Hematologic Malignancies, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
Am J Hematol 83:771-7. 2008..This study supports further investigation of immunotherapy in the post-intensive chemotherapy setting in the management of patients with AML...
- Optimizing treatment of chronic myeloid leukemia: a rational approachRichard M Stone
Dana Farber Cancer Institute, Boston, Massachusetts 02215, USA
Oncologist 9:259-70. 2004..Imatinib is now indicated as first-line therapy for CML in all phases...
- Prognostic factors in AML in relation to (ab)normal karyotypeRichard M Stone
Harvard Medical School, Dana Farber Cancer Institute, Boston MA 02115 6084, USA
Best Pract Res Clin Haematol 22:523-8. 2009....
- High dose cytarabine plus gemtuzumab ozogamicin for patients with relapsed or refractory acute myeloid leukemia: Cancer and Leukemia Group B study 19902Richard M Stone
Dana Farber Cancer Institute, Boston, MA 02115, USA
Leuk Res 35:329-33. 2011..Median overall survival was 8.9 months. No grade 4 hepatic veno-occlusive disease was observed. This regimen merits further study, both in this setting and as a remission consolidation therapy...
- Targeted agents in AML: much more to doRichard M Stone
Adult Leukemia Program, Dana Farber Cancer Institute and Harvard Medical School, 44 Binney Street, D 840 Boston, MA 02115, USA
Best Pract Res Clin Haematol 20:39-48. 2007..On the other hand, nascent attempts with mild success have been achieved, yielding hope that this strategy will bear real fruit in the future...
- New agents in post-remission therapyRichard M Stone
Harvard Medical School, Boston, MA 02115, USA
Best Pract Res Clin Haematol 23:475-9. 2010..While intensive chemotherapy has little utility, the optimal post-remission therapy for older adults remains unclear, though reduced-intensity conditioning allogeneic stem cell transplant is being used with increasing frequency...
- Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412Richard M Stone
Dana Farber Cancer Institute, Boston, MA 02115, USA
Blood 105:54-60. 2005..PKC412 is an oral tyrosine kinase inhibitor with clinical activity in patients with AML whose blasts have an activating mutation of FLT3, suggesting potential use in combination with active agents, such as chemotherapy...
- Postremission therapy in older patients with de novo acute myeloid leukemia: a randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabineR M Stone
Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
Blood 98:548-53. 2001..These results suggest the need to develop novel therapeutic strategies for these patients. (Blood. 2001;98:548-553)..
- Are new agents really making a difference in MDS?Richard M Stone
Harvard Medical School, Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
Best Pract Res Clin Haematol 21:639-46. 2008..Treating MDS remains a challenge despite the availability of new agents, such as lenalidomide, azacitidine, and decitabine. Whether these drugs have made a real difference in treating this group of diseases remains controversial...
- Should the presence of minimal residual disease (MRD) in morphologic complete remission alter post-remission strategy in AML?Richard M Stone
Harvard Medical School, Boston, MA 02215, USA
Best Pract Res Clin Haematol 24:509-14. 2011..Proving that MPF-defined MRD should prompt a change in treatment plan optimally requires a contemporaneous control group or at least a historical control treated in standard fashion...
- Quantitative monitoring by polymerase colony assay of known mutations resistant to ABL kinase inhibitorsV Nardi
Division of Hematology Oncology, Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Children s Hospital Boston, Boston, MA 02115, USA
Oncogene 27:775-82. 2008..Finally, this methodology could be a valuable research tool to shed light on the natural behavior of mutations pre-existing kinase inhibitors therapy and either disappearing over time or slowly taking over...
- KIAA1509 is a novel PDGFRB fusion partner in imatinib-responsive myeloproliferative disease associated with a t(5;14)(q33;q32)R L Levine
Division of Hematology, Brigham and Women s Hospital, Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA
Leukemia 19:27-30. 2005..Imatinib therapy resulted in rapid normalization of the patient's blood counts, and subsequent bone marrow biopsies and karyotypic analysis were consistent with sustained complete remission...
- Postremission therapy in adults with acute myeloid leukemiaR M Stone
Dana-Farber Cancer Institute, Boston, MA 02115, USA
Semin Hematol 38:17-23. 2001..Because the relapse rate is so high, new therapies for AML, such as signaling and immunotherapeutic approaches, are the focus of active investigation...
- Induction and postremission therapy: new agentsR M Stone
Adult Leukemia Program, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
Leukemia 17:496-8. 2003
- PKC 412 FLT3 inhibitor therapy in AML: results of a phase II trialR M Stone
Dana Farber Cancer Institute, Boston, MA, USA
Ann Hematol 83:S89-90. 2004
- Torsades de pointes associated with voriconazole useJ A Philips
Division of Infectious Diseases, Brigham and Women s Hospital, Boston, MA 02115, USA
Transpl Infect Dis 9:33-6. 2007..The potential for synergistic cardiotoxicity must be carefully considered...
- SYK regulates mTOR signaling in AMLJ Carnevale
Department of Pediatric Oncology, Dana Farber Cancer Institute and Children s Hospital Boston, Harvard Medical School, Boston, MA, USA
Leukemia 27:2118-28. 2013..These studies reveal SYK as a regulator of mTOR and MAPK signaling in AML and demonstrate that inhibition of PI3K pathway activity enhances the effects of SYK inhibition on AML cell viability and differentiation. ..
- CD6+ donor marrow T-cell depletion as the sole form of graft-versus-host disease prophylaxis in patients undergoing allogeneic bone marrow transplant from unrelated donorsR J Soiffer
Department of Adult Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
J Clin Oncol 19:1152-9. 2001..Herein, we report results in the first 48 recipients of unrelated marrow using CD6+ TCD as the sole form of GVHD prophylaxis...
- Recent advances in low- and intermediate-1-risk myelodysplastic syndrome: developing a consensus for optimal therapyRichard Stone
Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA
Clin Adv Hematol Oncol 6:1-15. 2008..This clinical roundtable will discuss the optimal management of patients with each of these approved therapies, as well as the various classification systems used to differentiate MDS subtypes for treatment...
- All-trans retinoic acid induces monocyte growth factor receptor (c-fms) gene expression in HL-60 leukemia cellsH C Hsu
Laboratory of Clinical Pharmacology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115
Leukemia 7:458-62. 1993..Our results indicate that retinoic acid can induce features of both monocytic and granulocytic differentiation in HL-60 cells...
- Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndromeEdwin P Alyea
Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
Biol Blood Marrow Transplant 12:1047-55. 2006..These results suggest that NST is a reasonable alternative for patients with advanced AML and MDS at high risk for complications after myeloablative transplantation...
- Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412Joseph D Growney
Division of Hematology, Department of Medicine, Brigham and Women s Hospital, Boston, MA, USA
Blood 106:721-4. 2005..These findings suggest that PKC412 may be a useful therapeutic agent for c-KIT-positive malignancies harboring the imatinib mesylate-resistant D816V or D816Y activation mutations...
- Potentiation of antileukemic therapies by the dual PI3K/PDK-1 inhibitor, BAG956: effects on BCR-ABL- and mutant FLT3-expressing cellsEllen Weisberg
Department of Medical Oncology Hematologic Neoplasia, Dana Farber Cancer Institute, Boston, MA 02115, USA
Blood 111:3723-34. 2008..Finally, BAG956 and rapamycin/RAD001 were shown to combine in a nonantagonistic fashion against BCR-ABL- and mutant FLT3-expressing cells both in vitro and in vivo...
- A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndromeJan Cools
Brigham and Women s Hospital and Harvard Medical School, Boston, USA
N Engl J Med 348:1201-14. 2003..Recent reports of responses to imatinib in patients with the syndrome suggested that an activated kinase such as ABL, platelet-derived growth factor receptor (PDGFR), or KIT, all of which are inhibited by imatinib, might be the cause...
- Evolving strategies in the treatment of MDS and AMLRichard Stone
Harvard University School of Medicine, Boston, Massachusetts, USA
Clin Adv Hematol Oncol 7:1-14; quiz 2 p following 14. 2009..By becoming familiar with these studies, the physician will be better able to provide the optimal treatment for their patients, as well as become aware of novel therapeutic strategies to offer their patients in ongoing clinical trials...
- Antileukemic effects of the novel, mutant FLT3 inhibitor NVP-AST487: effects on PKC412-sensitive and -resistant FLT3-expressing cellsEllen Weisberg
Department of Medical Oncology Hematologic Neoplasia, Dana Farber Cancer Institute, Boston, MA, USA
Blood 112:5161-70. 2008..Thus, we present a novel class of FLT3 inhibitors that displays high selectivity and potency toward FLT3 as a molecular target, and which could potentially be used to override drug resistance in AML...
- Protein disulfide isomerases are antibody targets during immune-mediated tumor destructionCatia Fonseca
Department of Medical Oncology and Cancer Vaccine Center, Dana Farber Cancer Institute, Boston, MA 02115, USA
Blood 113:1681-8. 2009..Together, these findings reveal the unexpected immunogenicity of PDIs and raise the possibility that these gene products might serve as targets for therapeutic monoclonal antibodies...
- Older adults with acute myeloid leukemiaMikkael A Sekeres
Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
Curr Oncol Rep 4:403-9. 2002..Herein we characterize the intrinsic biologic features of AML as it occurs in the older population, review currently available therapeutic approaches, and discuss therapeutic strategies in development...
- Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia cellsEllen Weisberg
Department of Medical Oncology Hematologic Neoplasia, Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
Mol Cancer Ther 7:1121-9. 2008..This in vitro system helped to elucidate stromal-secreted viability factors that may play a role in stromal-mediated cytoprotection of tyrosine kinase inhibitor-treated leukemia cells...
- Chromosome 5q deletion and epigenetic suppression of the gene encoding alpha-catenin (CTNNA1) in myeloid cell transformationTing Xi Liu
Laboratory of Development and Diseases, Institute of Health Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences and Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China
Nat Med 13:78-83. 2007..Thus, loss of expression of the alpha-catenin tumor suppressor in hematopoietic stem cells may provide a growth advantage that contributes to human MDS or AML with del(5q)...
- Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801Daniel J DeAngelo
Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
Blood 109:5136-42. 2007..The 1-year overall survival was 28% (95% CI, 15%, 43%). Nelarabine is well tolerated and has significant antitumor activity in relapsed or refractory T-ALL and T-LBL...
- Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate allelesStefan Fröhling
Division of Hematology, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
Cancer Cell 12:501-13. 2007....
- Impact of cytogenetics on outcome of de novo and therapy-related AML and MDS after allogeneic transplantationPhilippe Armand
Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
Biol Blood Marrow Transplant 13:655-64. 2007....
- Phase I and pharmacokinetic study of bortezomib in combination with idarubicin and cytarabine in patients with acute myelogenous leukemiaEyal C Attar
Hematology Oncology Unit, Massachusetts General Hospital, Boston, MA 02114, USA
Clin Cancer Res 14:1446-54. 2008..We conducted this phase I study to determine if the proteasome inhibitor bortezomib could be safely added to induction chemotherapy in patients with acute myelogenous leukemia (AML)...
- Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5qAzra Raza
Rush University Medical Center, Chicago, IL, USA
Blood 111:86-93. 2008..Lenalidomide has clinically meaningful activity in transfusion-dependent patients with low- or int-1-risk MDS who lack the deletion 5q karyotypic abnormality...
- Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatmentAndreas Hochhaus
Medizinische Fakultaet Mannheim, University of Heidelberg, Mannheim, Germany
Blood 111:1039-43. 2008..5 years, compared with earlier time points. Imatinib continues to be an effective and safe therapy for patients with CP CML after failure of IFN...
- Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)John C Byrd
Division of Hematology and Oncology, Comprehensive Cancer Center, The Ohio State University, Columbus 43210 1240, USA
Blood 100:4325-36. 2002....
- A 2-gene classifier for predicting response to the farnesyltransferase inhibitor tipifarnib in acute myeloid leukemiaMitch Raponi
Veridex, 3210 Merryfield Row, La Jolla, CA 92121, USA
Blood 111:2589-96. 2008..Therefore, these data indicate that a 2-gene expression assay may have utility in categorizing a population of patients with AML who are more likely to respond to tipifarnib...
- Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720Maria R Baer
University of Maryland Greenebaum Cancer Center, Baltimore, MD 21201, USA
J Clin Oncol 26:4934-9. 2008..Cancer and Leukemia Group B (CALGB) 9720 evaluated subcutaneous low-dose recombinant interleukin-2 (rIL-2) maintenance immunotherapy as a strategy for prolonging remission in older patients with acute myeloid leukemia (AML)...
- Feasibility of administering oblimersen (G3139; Genasense) with imatinib mesylate in patients with imatinib resistant chronic myeloid leukemia--Cancer and leukemia group B study 10107Meir Wetzler
Leukemia Section, Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
Leuk Lymphoma 49:1274-8. 2008..Although the combination of oblimersen and IM is safe and feasible, we did not observe clinical benefit in these patients with imatinib-resistant CML using these doses and schedule...
- Five-year follow-up of patients receiving imatinib for chronic myeloid leukemiaBrian J Druker
Oregon Health and Science University Cancer Institute, L592, 3181 SW Sam Jackson Park Rd, Portland, OR 97239, USA
N Engl J Med 355:2408-17. 2006..Imatinib inhibits this kinase, and in a short-term study was superior to interferon alfa plus cytarabine for newly diagnosed CML in the chronic phase. For 5 years, we followed patients with CML who received imatinib as initial therapy...
- Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapyAndreas Hochhaus
III Medizinische Klinik, Medizinische Fakultat Mannheim, Universitat Heidelberg, Theodor Kutzer Ufer 1 3, 68167 Mannheim, Germany
Blood 109:2303-9. 2007..This trial was registered at www.clinicaltrials.gov as CA180013...
- Identifying and characterizing a novel activating mutation of the FLT3 tyrosine kinase in AMLJingrui Jiang
Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney St, D720C, Boston, MA 02115, USA
Blood 104:1855-8. 2004..These results suggest that mutations at N841 represent a significant new activating mutation in patients with AML and that patients with such mutations may respond to small-molecule FLT3 inhibitors such as PKC412...
- Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantationMartha Wadleigh
Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
Blood 102:1578-82. 2003..Three of 14 patients who received GO prior to SC transplantation died of VOD. We conclude that patients undergoing SC transplantation within a short interval from GO administration are at increased risk of developing VOD...
- Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of ageEdwin P Alyea
Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
Blood 105:1810-4. 2005..052). Our experience suggests that, in patients over age 50, NST with fludarabine and low-dose busulfan leads to an overall outcome at least as good as that following myeloablative therapy...
- PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorderJing Chen
Howard Hughes Medical Institute, Harvard Medical School, Boston, MA 02115, USA
Proc Natl Acad Sci U S A 101:14479-84. 2004..Therefore, PKC412 may be a useful therapy for treatment of human stem cell leukemia-lymphoma syndrome...
- Comparable outcome with T-cell-depleted unrelated-donor versus related-donor allogeneic bone marrow transplantationEdwin P Alyea
Biol Blood Marrow Transplant 8:601-7. 2002..However, these adverse events do not lead to inferior probability of relapse-free survival because they are accompanied by a reduction in relapse rates...
- Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host diseaseDaniel J DeAngelo
Dana Farber Cancer Institute, Department of Adult Oncology, Boston, Massachusetts 02115, USA
Clin Cancer Res 10:5065-71. 2004..Recent reports indicate that imatinib mesylate (Gleevec) can induce remissions in these patients as well. Less is known about the extent and durability of these responses...
- Platelet-derived growth factor receptor inhibition to treat idiopathic hypereosinophilic syndromeRichard M Stone
Adult Leukemia Program, Dana Farber Cancer Institute, Boston, MA 02115, USA
Semin Oncol 31:12-7. 2004..The efficacy of relatively low imatinib concentrations in HES, mediated by inhibition of FIP1L1-PDGFRalpha kinase activity, causally implicates FIP1L1-PDGFRA in the pathogenesis in certain HES patients...
- Differences in prognostic factors and outcomes in African Americans and whites with acute myeloid leukemiaMikkael A Sekeres
Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Department of Hematology and Medical Oncology, The Cleveland Clinic Foundation, Desk R35, 9500 Euclid Ave, Cleveland, OH 44195, USA
Blood 103:4036-42. 2004..African Americans and whites with AML differ with respect to important prognostic factors. African American men have worse CR rates and overall survival than whites and African American women, and should be considered a poor-risk group...
- PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRα-induced myeloproliferative diseaseJan Cools
Division of Hematology, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
Cancer Cell 3:459-69. 2003..Our data establish PKC412 as molecularly targeted therapy for HES and other diseases expressing activated PDGFRalpha and demonstrate the potential of alternative kinase inhibitors to overcome resistance in target tyrosine kinases...
- Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domainFlorian Heidel
3rd Medical Department, Johannes Gutenberg University Mainz Langenbeckstrasse 1, 55101 Mainz, Germany
Blood 107:293-300. 2006..These studies point out that a genetically complex malignancy such as AML may retain dependence on a single oncogenic signal...
- Treatment of acute myeloid leukemia: state-of-the-art and future directionsRichard M Stone
Dana Farber Cancer Institute, Brigham and Women s Hospital, and Harvard Medical School, Boston, MA 02115, USA
Semin Hematol 39:4-10. 2002..Such targeted therapeutics offer the promise of novel antileukemic activity combined with an improved therapeutic index...
- Acute myeloid leukemia clinical practice guidelines in oncologyMargaret R O'Donnell
City of Hope Cancer Center, Los Angeles, CA, USA
J Natl Compr Canc Netw 4:16-36. 2006
- Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II studyCharles L Sawyers
Department of Medicine and Molecular Biology Institute, University of California, Los Angeles, CA 90095, USA
Blood 99:3530-9. 2002..Additional clinical studies are warranted to explore the efficacy and feasibility of imatinib used in combination with other antileukemic drugs...
- Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamicsDaniel J DeAngelo
Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
Blood 108:3674-81. 2006..Tandutinib at the MTD (525 mg twice daily) should be evaluated more extensively in patients with AML with FLT3-ITD mutations to better define its antileukemic activity...
- Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group BLewis R Silverman
Division of Medical Oncology, Mount Sinai School of Medicine and Memorial Sloan Kettering Cancer Center, Box 1129, One Gustave L Levy Place, New York, NY 10029, USA
J Clin Oncol 20:2429-40. 2002..Supportive care is standard therapy. We previously reported that azacitidine (Aza C) was active in patients with high-risk MDS...
- Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: a cancer and leukemia group B studySherif S Farag
Division of Hematology and Oncology, Department of Internal Medicine, The Ohio State University, A433A Starling Loving Hall, 320 W Tenth Avenue, Columbus, OH 43210, USA
J Clin Oncol 23:482-93. 2005..Evaluate the outcome of induction and postremission therapy in adults younger than 60 years with normal cytogenetics acute myeloid leukemia (AML)...
- Quantitative real-time RT-PCR monitoring of BCR-ABL in chronic myelogenous leukemia shows lack of agreement in blood and bone marrow samplesWendy Stock
University of Chicago Cancer Research Center, Chicago, IL 60637, USA
Int J Oncol 28:1099-103. 2006..Based on these results, we caution against interchanging BM with PB sampling for MRD monitoring during treatment of CML since this may lead to misinterpretation of treatment results...
- Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461Sherif S Farag
Division of Hematology and Oncology, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA
Blood 108:63-73. 2006..Patients with complex > or = 5 appear to benefit minimally from current treatment and are better suited for investigational therapy or supportive care...
- Myelodysplastic syndromes clinical practice guidelines in oncologyPeter L Greenberg
Stanford Hospital and Clinics, Stanford, CA, USA
J Natl Compr Canc Netw 4:58-77. 2006
- The challenge of acute myeloid leukemia in older patientsMikkael A Sekeres
Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
Curr Opin Oncol 14:24-30. 2002..Future directions include therapies targeted at immunomodulation, at angiogenesis, and in particular against intracellular signals that promote proliferation at the expense of differentiation...
- Lineage specific treatment of adult patients with acute lymphoblastic leukemia in first remission with anti-B4-blocked ricin or high-dose cytarabine: Cancer and Leukemia Group B Study 9311Ted P Szatrowski
Weill Medical College of Cornell University, New York, New York, USA
Cancer 97:1471-80. 2003..Anti-B4-blocked ricin is an immunotoxin comprised of an anti-CD19 murine monoclonal antibody (B4) conjugated to blocked ricin, which has cytotoxic activity in patients with lymphoid malignancies...
- Quantitative monitoring of BCR/ABL transcript during STI-571 therapyCatherine J Wu
Center for Hematologic Oncology, Department of Biostatistics, Dana Farber Cancer Institute, Boston, MA 02115, USA
Leuk Lymphoma 43:2281-9. 2002..0008 at 6, 9 and 12 months, respectively). Our results demonstrate that PBMC BCR/ABL mRNA levels correlate well with response to STI-571. This non-invasive, rapid and sensitive PCR-based assay can be used to monitor response to STI-571...
- The difficult problem of acute myeloid leukemia in the older adultRichard M Stone
Adult Acute Leukemia Program, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA, USA
CA Cancer J Clin 52:363-71. 2002..Advances in our understanding of the pathophysiology of AML and promising early clinical data suggest that the era of truly targeted therapy in this difficult disease may soon be a reality...
- Isolated trisomy of chromosomes 8, 11, 13 and 21 is an adverse prognostic factor in adults with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B 8461Sherif S Farag
Division of Hematology and Oncology, Department of Internal Medicine, The Ohio State University, A433A Starling Loving Hall, 320 West Tenth Avenue, Columbus, OH 43210, USA
Int J Oncol 21:1041-51. 2002..We conclude that in de novo adult AML patients not receiving SCT, IT(C) appears to independently predict a poor outcome that may be improved with SCT in first remission. Prospective studies are required to confirm this hypothesis...
- Fatal hepatic necrosis following imatinib mesylate therapyNancy U Lin
Blood 102:3455-6. 2003
- Fifty years of clinical research by the leukemia committee of the cancer and leukemia group BRichard A Larson
Department of Medicine and Cancer Research Center, University of Chicago, Chicago, Illinois, USA
Clin Cancer Res 12:3556s-63s. 2006....
- Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasiaBruce D Cheson
Department of Hematology Oncology, Georgetown University Hospital, Washington, DC, USA
Blood 108:419-25. 2006..Because limitations of the IWG criteria have surfaced, based on practical and reported experience, some modifications were warranted. In this report, we present recommendations for revisions of some of the initial criteria...
- Is intravenous arsenic trioxide a useful therapy in myelodysplastic syndromes?Richard M Stone
J Clin Oncol 24:2414-6. 2006
- Acute promyelocytic leukemia: current strategies for the treatment of newly diagnosed diseaseL Andres Sirulnik
Dept of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, 44 Binney Street, Boston, MA 02116, USA
Clin Adv Hematol Oncol 3:391-7, 429. 2005..We also highlight practical points that may serve as a guideline for the treating physician and address current controversies in the choice of treatment...
- Failure to define window of time for autologous tumor vaccination in patients with newly diagnosed or relapsed acute lymphoblastic leukemiaW Nicholas Haining
Department of Pediatric Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
Exp Hematol 33:286-94. 2005....
- After chronic myelogenous leukemia: tyrosine kinase inhibitors in other hematologic malignanciesMartha Wadleigh
Division of Hematologic Malignancy, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
Blood 105:22-30. 2005..This review focuses on tyrosine kinases that have been implicated in the pathogenesis of hematologic diseases other than chronic myelogenous leukemia and discusses the evidence for the use of small molecules to target these kinases...
- End points to establish the efficacy of new agents in the treatment of acute leukemiaFrederick R Appelbaum
Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
Blood 109:1810-6. 2007..In this report, we present the results of that effort...
- Recurrent acute promyelocytic leukemia presenting as a sacral nerve root massSantosh Kesari
Department of Neurology, Dana Farber Cancer Institute Brigham and Women s Hospital, Boston, MA, USA
J Clin Oncol 26:3279-81. 2008
- The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute myelogenous leukemia in adults: an evidence-based reviewDenise M Oliansky
Roswell Park Cancer Institute, Buffalo, New York 14263, USA
Biol Blood Marrow Transplant 14:137-80. 2008..conventional conditioning in older (>60 years) and intermediate (40-60 years) aged adults? (4) What is the impact on survival outcomes of unrelated donor HSCT vesus chemotherapy in younger (<40 years) adults with high risk disease?..